QI
GSK icon

Qtron Investments’s GSK GSK Stock Holding History

Qtron Investments’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24M Sell
23,713
-957
-4% -$50.6K 0.17% 124
2026
Q1 		$1.36M Buy
24,670
+4,343
+21% +$235K 0.18% 121
2025
Q4 		$997K Buy
20,327
+8,347
+70% +$389K 0.13% 181
2025
Q3 		$517K Sell
11,980
-41
-0.3% -$1.6K 0.06% 320
2025
Q2 		$462K Hold
12,021
– – 0.06% 344
2025
Q1 		$466K Sell
12,021
-11,154
-48% -$408K 0.07% 305
2024
Q4 		$784K Sell
23,175
-16,488
-42% -$594K 0.11% 239
2024
Q3 		$1.62M Sell
39,663
-7
-0% -$286 0.22% 96
2024
Q2 		$1.53M Buy
39,670
+7,859
+25% +$331K 0.22% 95
2024
Q1 		$1.36M Hold
31,811
– – 0.19% 122
2023
Q4 		$1.18M Hold
31,811
– – 0.19% 120
2023
Q3 		$1.15M Buy
31,811
+6,638
+26% +$236K 0.22% 103
2023
Q2 		$897K Sell
25,173
-7,772
-24% -$279K 0.17% 158
2023
Q1 		$1.17M Sell
32,945
-1,608
-5% -$56.3K 0.24% 100
2022
Q4 		$1.21M Buy
34,553
+24,632
+248% +$820K 0.26% 97
2022
Q3 		$292K Sell
9,921
-24,504
-71% -$929K 0.07% 339
2022
Q2 		$1.87M Sell
34,425
-1,249
-4% -$69K 0.41% 52
2022
Q1 		$1.94M Hold
35,674
– – 0.43% 51
2021
Q4 		$1.97M Buy
35,674
+9,201
+35% +$479K 0.44% 49
2021
Q3 		$1.26M Buy
26,473
+17,444
+193% +$876K 0.34% 68
2021
Q2 		$449K Hold
9,029
– – 0.11% 223
2021
Q1 		$403K Buy
9,029
+477
+6% +$21.7K 0.11% 222
2020
Q4 		$393K Sell
8,552
-2,013
-19% -$92.5K 0.11% 231
2020
Q3 		$497K Sell
10,565
-5,239
-33% -$262K 0.17% 141
2020
Q2 		$806K Sell
15,804
-4,676
-23% -$240K 0.32% 70
2020
Q1 		$970K Buy
20,480
+2,000
+11% +$107K 0.58% 39
2019
Q4 		$1.08M Buy
18,480
+2,664
+17% +$148K 0.63% 34
2019
Q3 		$844K Buy
+15,816
New +$814K 0.51% 52

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Qtron Investments's GSK Position: Q2 2026 in Review

Qtron Investments reduced its GSK (GSK) stake by 3.9% in Q2 2026, selling an estimated $50.6K and leaving 23,713 shares worth $1.24M. The position accounts for 0.17% of the portfolio, ranked #124.

Qtron Investments first reported a position in GSK in Q3 2019 and has held it in 28 quarters since. The position peaked at $1.97M in Q4 2021. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Qtron Investments held 23,713 shares of GSK worth $1.24M as of Q2 2026.
  • Qtron Investments sold 957 GSK shares in Q2 2026, an estimated $50.6K.
  • GSK made up 0.17% of Qtron Investments's portfolio in Q2 2026, its #124 holding.
  • Qtron Investments first reported a position in GSK in Q3 2019 and has held it in 28 quarters since.
  • Qtron Investments's GSK position peaked at $1.97M in Q4 2021.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Qtron Investments's 13F filing for Q2 2026, filed 13 Aug 2026.